Chenglong Liu

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 10

Top Topics

Epithelial Mesenchymal Transition

Top Venues

Journal of medicinal chemistry

Cancer discovery

Molecular pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry (2023)
Hao Zhang, Chenglong Liu, Qiushi Chen, Li-An Shen, Wenting Xiao, Jiayi Li, Yonghui Wang, Di Zhu, Qingwei Zhang, Jianqi Li
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Journal of medicinal chemistry 66 (2) (2023)
Fan Yang, Chenglong Liu, Pengyuan Li, Aihua Wu, Yue Ma-Lauer, Hao Zhang, Zhuang Su, Wei Lu, Albrecht von Brunn, Di Zhu
Targeting Cyclophilin A and CD147 to Inhibit Replication of SARS-CoV-2 and SARS-CoV-2-Induced Inflammation . Molecular pharmacology (2023)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry (2022)
Bo Hu, Mincheng Yu, Xiaolu Ma, Jia-Lei Sun, Chenglong Liu, Chunyan Wang, Suiyi Wu, Pei-Yao Fu, Zhen Yang, Yungang He, Yuanyuan Zhu, Cheng Huang, Xin-Rong Yang, Yinghong Shi, Shuangjian Qiu, Huichuan Sun, Andrew X Zhu, Jian Zhou, Yang Xu, Di Zhu, Jia Fan
IFNα Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. Cancer discovery 12 (7) (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)
Hao Zhang, Chenglong Liu, Di Zhu, Qingwei Zhang, Jianqi Li
Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners. Journal of medicinal chemistry 66 (1) (2022)